SUMMARY
# Anti-Tau Immunotherapy Dosing Optimization
## Background and Rationale
This clinical optimization study focuses on establishing optimal dosing regimens for tau-targeting immunotherapies in Alzheimer's disease patients. Given the critical role of tau pathology in AD progression and the promising but variable results from early-phase tau immunotherapy trials, this research addresses the urgent need for evidence-based dosing strategies. The study employs a systematic dose-escalation design to eva
METHODOLOGY NOTES
**Phase 1: Patient Recruitment and Screening (Months 1-3)**
• Recruit 240 patients with mild-to-moderate Alzheimer's disease (MMSE 14-26, CDR 0.5-2.0)
• Conduct comprehensive screening including tau-PET imaging, CSF biomarkers (p-tau181, p-tau217), MRI, neuropsychological assessment
• Exclude patients with active autoimmune conditions, previous immunotherapy exposure, or contraindications to MRI
• Stratify patients by baseline tau burden (low: <1.5 SUVR, moderate: 1.5-2.0 SUVR, high: >2.0 SUVR)
**Phase 2: Randomization and Baseline Assessment (Month 4)**
• Randomize patients to 6 treatment arms (n=40 each): placebo, anti-tau antibody at 0.5mg/kg Q4W, 1.0mg/kg Q4W, 2.0mg/kg Q4W, 1.0mg/kg Q2W, 2.0mg/kg Q2W
• Collect baseline measurements: ADAS-Cog13, CDR-SB, ADCS-ADL, tau-PET SUVR, CSF p-tau levels, plasma NfL, brain volume via MRI
• Establish safety monitoring committee with predefined stopping rules
**Phase 3: Treatment Administration (Months 5-16)**
• Administer intravenous anti-tau